Sigilon Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Sigilon Therapeutics

12/05/2022 23:26

* Sigilon Therapeutics Inc  SGTX.OQ  reported a quarterly
adjusted
loss of 43 cents​​ per share for the quarter ended in March. The
mean expectation of four analysts for the quarter was for a loss
of 33 cents per share.
    * Revenue rose 7% to $3.17 million from a year ago; 
analysts
expected $2.00 million. 
    * Sigilon Therapeutics Inc's reported EPS for the quarter
was a
loss of 43 cents​.
    * The mean earnings estimate of analysts had risen by
about 2.2%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Sigilon Therapeutics Inc shares had fallen by 43.8% this
quarter and lost 70.1% so far this year.
    * The company reported a quarterly loss of $13.86 million.
    * Wall Street's median 12-month price target for Sigilon
Therapeutics Inc is $3.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 12 at 10:25 p.m.  ​All
figures in US dollars unless otherwise stated